DK2729147T3 - NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA - Google Patents

NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA Download PDF

Info

Publication number
DK2729147T3
DK2729147T3 DK12741268.2T DK12741268T DK2729147T3 DK 2729147 T3 DK2729147 T3 DK 2729147T3 DK 12741268 T DK12741268 T DK 12741268T DK 2729147 T3 DK2729147 T3 DK 2729147T3
Authority
DK
Denmark
Prior art keywords
methyl
phenyl
fluoro
trifluoromethyl
compound
Prior art date
Application number
DK12741268.2T
Other languages
Danish (da)
English (en)
Inventor
Giulio Ferrari
Original Assignee
Irbm - Science Park S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irbm - Science Park S P A filed Critical Irbm - Science Park S P A
Application granted granted Critical
Publication of DK2729147T3 publication Critical patent/DK2729147T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12741268.2T 2011-07-04 2012-07-04 NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA DK2729147T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161504265P 2011-07-04 2011-07-04
PCT/EP2012/063067 WO2013004766A1 (en) 2011-07-04 2012-07-04 Nk-1 receptor antagonists for treating corneal neovascularisation

Publications (1)

Publication Number Publication Date
DK2729147T3 true DK2729147T3 (en) 2017-12-18

Family

ID=46601758

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12741268.2T DK2729147T3 (en) 2011-07-04 2012-07-04 NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA

Country Status (6)

Country Link
US (2) US9782397B2 (enExample)
EP (1) EP2729147B1 (enExample)
DK (1) DK2729147T3 (enExample)
ES (1) ES2672099T3 (enExample)
NO (1) NO2729147T3 (enExample)
WO (1) WO2013004766A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2971096T3 (es) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CA3026118A1 (en) * 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
EP3589369A4 (en) 2017-01-09 2020-03-18 DAS-MG, Inc. USE AND COMPOSITION FOR TREATING SEVERE MYASTHENIA AND OTHER MYASTHENIC SYNDROMES
WO2019023175A1 (en) * 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
CN111918647A (zh) * 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
WO2019191391A1 (en) * 2018-03-28 2019-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment and prevention of alpha herpes virus infection
US20230134843A1 (en) * 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919205A (en) 1972-07-17 1975-11-11 Squibb & Sons Inc Dithiocarbonylthioacetyl cephalosporin derivatives
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2103269C1 (ru) 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
US5629347A (en) 1991-07-05 1997-05-13 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5552534A (en) 1991-08-22 1996-09-03 The Trustees Of The University Of Pennsylvania Non-Peptide peptidomimetics
DE69231395T3 (de) 1991-09-20 2005-07-21 Glaxo Group Ltd., Greenford Neue medizinische Indikation für Tachykinin-Antagonisten
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
WO1993017032A1 (en) 1992-02-24 1993-09-02 The Trustees Of The University Of Pennsylvania Techniques and intermediates for preparing non-peptide peptidomimetics
FR2689889B1 (fr) 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, et leur preparation.
TW241258B (enExample) 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IS4208A (is) 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
FR2718136B1 (fr) 1994-03-29 1996-06-21 Sanofi Sa Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
JPH10506399A (ja) 1994-09-30 1998-06-23 ノバルティス アクチェンゲゼルシャフト 1−アシル−4−マリファチルアミノピペリジン化合物
CN1081625C (zh) 1995-02-22 2002-03-27 诺瓦提斯公司 1-芳基-2-酰氨基乙烷化合物和它们作为神经激肽尤其是神经激肽1拮抗剂的用途
GB9505692D0 (en) 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
CA2216701A1 (en) 1995-03-27 1996-10-03 Akira Okayama Piperidine derivatives
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
GB9510600D0 (en) 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
WO1998017660A1 (en) 1996-10-25 1998-04-30 Merck & Co., Inc. Phenyl spiroethercycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
GB9700597D0 (en) 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
JPH10259184A (ja) 1997-03-18 1998-09-29 Takeda Chem Ind Ltd 三環性複素環化合物の製造法
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
HRP20000066A2 (en) 1997-08-06 2000-10-31 Lilly Co Eli 2-acylaminopropanamines as tachykinin receptor antagonists
TW426667B (en) 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
CO5150225A1 (es) 1999-03-19 2002-04-29 Merck Sharp & Dohme Derivados del tetrahidropirano y su uso como agentes terapeuticos
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
KR20020000640A (ko) 1999-05-10 2002-01-05 아코르디스 인두스트리알 피베르스 게엠베하 필라멘트 형성성 폴리에스테르와 코폴리에스테르 및이들의 제조방법
JP3229294B2 (ja) 1999-06-04 2001-11-19 キヤノン販売株式会社 被成膜面の改質方法及び半導体装置の製造方法
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
EP1219619B1 (en) 1999-10-07 2004-08-11 Hisamitsu Pharmaceutical Co. Inc. 3-amino-2-phenylpiperidine derivatives as substance p antagonists
WO2001077069A1 (en) 2000-04-06 2001-10-18 Astrazeneca Ab Naphthamide neurokinin antagonists for use as medicaments
ATE400563T1 (de) 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
GB0012240D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
CN1327997A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——Ras GTP酶激活蛋白9.57和编码这种多肽的多核苷酸
DE10036818A1 (de) 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
PE20020444A1 (es) 2000-09-22 2002-06-14 Merck & Co Inc Antagonistas de receptores de taquiquinina zwitterionica
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0114867D0 (en) 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
NZ533540A (en) 2002-01-18 2006-04-28 Kyorin Seiyaku Kk Fused bicyclic pyrimidine derivatives that act as effective tachykinin receptor antagonists such as NK1 to treat tachykinin receptor-related pathological conditions
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2004002334A (ja) 2002-03-25 2004-01-08 Tanabe Seiyaku Co Ltd 医薬組成物
EP1501809B1 (en) 2002-04-26 2008-01-16 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
US20060128752A1 (en) 2002-07-03 2006-06-15 Giuseppe Alvaro Chemical compounds
GB0215392D0 (en) 2002-07-03 2002-08-14 Glaxo Group Ltd Chemical compounds
GB0217068D0 (en) 2002-07-23 2002-08-28 Merck Sharp & Dohme Therapeutic agents
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
GB0310724D0 (en) 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
JPWO2005019225A1 (ja) 2003-08-21 2007-11-01 杏林製薬株式会社 Nk1受容体拮抗作用を有する化合物の製造方法及びその製造中間体
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
US8108430B2 (en) 2004-04-30 2012-01-31 Microsoft Corporation Carousel control for metadata navigation and assignment
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
AU2005312076A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
CN101068551A (zh) 2004-12-03 2007-11-07 默克公司 喹啉速激肽受体拮抗剂
US7354922B2 (en) 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
JP2008523147A (ja) 2004-12-14 2008-07-03 メルク エンド カムパニー インコーポレーテッド オクタヒドロピラノ[3,4−c]ピロールタキキニン受容体拮抗薬
EP1870396B1 (en) 2005-03-31 2012-10-31 Nippon Zoki Pharmaceutical Co. Ltd. Benzyloxypropylamine derivative
US20090048248A1 (en) 2005-12-22 2009-02-19 Devita Robert J Octahydropyrano[3,4-C]Pyrrole Tachykinin Receptor Antagonists
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
JP2007277231A (ja) 2006-03-16 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007136570A2 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. 5,6-fused pyrrolidine compounds useful as tachykinin receptor antagonists
US20100099651A1 (en) 2006-10-26 2010-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP2008239618A (ja) 2007-02-28 2008-10-09 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2170064A4 (en) 2007-06-22 2010-08-04 Merck Sharp & Dohme 6,5-pyrrolopiperidine tachykinin receptor antagonists
KR20160032271A (ko) * 2008-02-26 2016-03-23 산도즈 아게 모르폴린 유도체의 제조
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
DK2722045T3 (en) * 2009-11-18 2016-10-24 Helsinn Healthcare Sa PREPARATIONS FOR THE TREATMENT OF CENTRAL MEDIATED nausea and vomiting
KR102166277B1 (ko) 2013-04-12 2020-10-15 삼성전자주식회사 무선 통신 네트워크를 이용한 운전 지원 방법 및 장치와 그 시스템
US11935002B2 (en) 2019-05-23 2024-03-19 Capital One Services, Llc Multi-lender platform that securely stores proprietary information for generating offers

Also Published As

Publication number Publication date
EP2729147A1 (en) 2014-05-14
WO2013004766A1 (en) 2013-01-10
ES2672099T3 (es) 2018-06-12
NO2729147T3 (enExample) 2018-02-03
US9782397B2 (en) 2017-10-10
US20180021327A1 (en) 2018-01-25
US20140128395A1 (en) 2014-05-08
EP2729147B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
US20180021327A1 (en) Treatment of corneal neovascularization
US20220211632A1 (en) Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
Morrison et al. Advances in ophthalmic drug delivery
AU2017331444B2 (en) Intracameral drug delivery depots
KR20170094794A (ko) 수니티닙 제제 및 눈 장애의 치료에서의 그의 사용 방법
BRPI0608978A2 (pt) terapia ocular usando agonistas de receptor alfa-2 adrenérgico possuindo taxas de depuração anterior realçadas
TWI832920B (zh) 抑制軟性隱形眼鏡變質之眼科用組成物
WO2019182905A1 (en) Sap and peptidomimetics for treatment of eye disease
JP2024079810A (ja) キレート剤、浸透促進剤およびヒドロキシエチルセルロースを含む眼科疾患治療用製剤
WO2018056269A1 (ja) Jak阻害剤を含有する点眼剤
ES2980110T3 (es) Antagonistas de NK-1 para uso en el tratamiento del dolor ocular
JP6473274B1 (ja) 熱ゲル化人工涙液
JP2018048133A (ja) 炎症性眼疾患の治療及び/又は予防剤
US20230134843A1 (en) Treatment of stem cell deficiency
RU2847424C1 (ru) Контактная линза для доставки лекарственного средства
JP2016034936A (ja) 角膜上皮障害治療剤の組み合わせ
BR112019005594B1 (pt) Composição de depósito intracameral e uso da mesma para tratamento de uma condição ocular
BR122024018825A2 (pt) Composição de depósito e uso da mesma para tratamento de uma condição ocular
Kaplowitz et al. ChapterChapter 17: 17Updated Medical Treatment for Glaucoma